Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes
Status:
Unknown status
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Obesity is one of the characteristics of type 2 diabetes mellitus. Most of the obese diabetes
patients are combined with dyslipidemia or hypertension. The clustering of diabetes, obesity,
hypertension and dyslipidemia increases the risk of cardiovascular events for patients. GLP-1
(glucagon like peptide-1) is a kind of incretin discovered in recent years. It was reported
that beside its hypoglycemic and losing weight effects, activator of GLP-1 receptor could
decrease blood pressure and improve lipid metabolism. Therefore, activation of GLP-1 receptor
may become a new comprehensive treatment strategies for improving glucose and lipid
metabolism, blood pressure level and cardiovascular complication. But, it is lack of
evidence-based medicine proof on the relationship between GLP-1 and blood pressure or serum
lipid. So, investigators designed a prospective, randomized, open-label, active control
study, and try to evaluate the effects of activator of GLP-1 receptor (liraglutide) on
lowering blood pressure, improving vascular function and lipid metabolism in overweight or
obese type 2 diabetic patients with masked hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Third Affiliated Hospital of Third Military Medical University